Dysphagia With Normal EndoscopyNCT01444066
The Role Of Empiric Dilation In Patients With Dysphagia With Normal Endoscopy
A study testing Dilation of the esophagus in people with Dysphagia With Normal Endoscopy, run by Washington University School of Medicine at 2 sites in United States.
Trial summary
The goal of our study is to determine if stretching the esophagus with a rubber dilator helps patients with swallowing difficulties who have a normal appearing esophagus on upper endoscopy. Read more about this study
- Who is it for?
- Ages 18 to 99 years
- Conditions the study is for
- Dysphagia With Normal Endoscopy
- What is being tested?
- Dilation of the esophagus
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 30 participants
- Where
- 2 sitesUnited States
- Study dates
- Sep 2011to 24 Oct 2013
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 99 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients age: > 18 years.
- Outpatients undergoing EGD for dysphagia.
- Ability to provide written informed consent.
Who cannot join
- Abnormal endoscopy (stricture, abnormal motility or mucosa observed)
- Oropharyngeal dysphagia suspected based on history and physical examination
- History of CVA or other neurologic disorder
- Known connective tissue disease (SLE, scleroderma, CREST, RA)
- Known histopathology based esophageal motor disorder, e.g. achalasia
- Prior thoracic or foregut surgery (excluding cholecystectomy)
- Prior thoracic radiation therapy
- Hiatus hernia >2 cm as judged during EGD
Trial locations and contacts
2 sites in 1 country.
United States2 sites
Barnes Jewish Hospital
St Louis, Missouri, 63112
Washington University
St Louis, Missouri, 63112
About this study
The goal of our study is to determine if stretching the esophagus with a rubber dilator helps patients with swallowing difficulties who have a normal appearing esophagus on upper endoscopy. In order to do this we will perform a randomized controlled study, where patients will undergo esophageal dilation (stretching) with different diameter dilators. We will measure change in symptom severity between baseline (prior to dilation) and 1, 3, 6 and 12 months after the procedure
Read the detailed description
Dysphagia typically refers to the sensation of food being stuck in the throat or chest( esophageal dysphagia) as well as difficulty with the initiation of swallowing (oropharyngeal dysphagia). It is typically classified into oropharyngeal and esophageal dysphagia. Oropharyngeal dysphagia is typically the result of neuromuscular disease as well as head and neck malignancy and can be diagnosed on the basis of history and physical examination in most cases. Patients with esophageal dysphagia can further be sub-classified into two groups; those with obvious abnormality in the esophageal mucosa or motility on endoscopy and those with normal findings on endoscopic examination.
The diagnosis and treatment of patients with dysphagia and abnormal findings on endoscopy has been extensively studied and there are well-define practice guidelines availed on the subject. In contrast to this the management strategy for the group of patients with esophageal type dysphagia and a normal appearing esophagus on upper endoscopy (DNE) has been a topic of controversy for over a decade. Those patients with DNE are thought to fall into several categories, those with very subtle strictures and rings in the esophagus that are not seen during endoscopy, as well as patients with non-erosive reflux disease, eosinophilic esophagitis, primary motility disorders of the esophagus, and finally those with "functional" dysphagia (in whom no cause can be identified). Several approaches have been advocated for the evaluation and treatment of patients with DNE, including a trial of proton pump inhibitor therapy, obtaining random biopsies to exclude eosinophilic esophagitis and non-erosive reflux disease, referral for manometry and esophageal pH monitoring, as well as empiric esophageal dilation with a large caliber bougie. Of these options empiric esophageal dilation with a large diameter bougie has been the initial management approach recommended by the most recent AGA guidelines as well as many experts in the field of esophagology, for the treatment of DNE.
The initial evidence for empiric esophageal dilation in patients with DNE came from a retrospective study by Marshal et al, who found that 50% of patients experienced a sustained improvement in symptoms following dilation with a large diameter bougie. This was followed by a randomized controlled trial by Colon and coworkers, who again found a significant benefit to empiric esophageal bougie dilation. However, two randomized trials in the mid-2000's did not find any benefit to empiric esophageal dilation; although the dilation methods used in these studies differed from that used by Marshal and Colon et al. Despite these conflicting results empiric dilation continues to be popular by community gastroenterologists, and is perceived to be safe effective intervention for treating patients with DEN. A recent study by Olson et al found that empiric dilation for DNE was performed more commonly then dilation for dilation for esophageal strictures in the United States and is associated with a 0.65% complication rate. Additionally, in the current era of financial pressure on the medical community empiric dilation for DNE at the time of the first diagnostic upper endoscopy could lead to a significant savings if it is effective in relieving symptoms; by obviating the need for further diagnostic testing, medications and repeat endoscopy.
With this in mind, our goal is to conduct a randomized controlled trial evaluating the role of empiric dilation in patients with DNE, to help fill existing gaps in the medical literature. Specifically, prior studies are lacking with regard to three important points. First, esophageal manometry and pH monitoring were not uniformly performed on patients; this testing is crucial to excluding esophageal motility disorders and non-erosive reflux disease, which are thought to be causes of DNE. Second, esophageal biopsies were not performed in any of the studies; this has become a standard part of the evaluation of all patients with DNE over the past 5 years, as eosinophilic esophagitis and non-erosive reflux disease can lead to dysphagia and may be missed without microscopic examination of the esophageal mucosa. Finally, none of the studies used a standardized and validated dysphagia questionnaire, such as the Mayo Dysphagia Questionnaire (MDQ) to evaluate symptoms.
- Conditions
- Dysphagia With Normal Endoscopy
- Being tested
- Dilation of the esophagus
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Dilation of the esophagusProcedure or surgery
Esophagus will be dilated with a Savory dilator.
| Study group | Role | What they receive |
|---|---|---|
| dilation to 27 French | Placebo comparator | Not described Receives: Procedure: Dilation of the esophagus |
| Dilation of the esophagus to 54 French | Experimental | Esophagus will be dilated with a Savory dilator Receives: Procedure: Dilation of the esophagus |
What is being measured
The primary outcome is the main question the study is designed to answer.
Improvement in dysphagia, quantified using 10 cm VAS scale
Measured: 12 months
Secondary outcomes (3)
Evaluate the yield of esophageal biopsy in patients with dysphagia with normal endoscopy
Measured: 12 months
Evaluate the yield of HRM and pH monitoring in patients with dysphagia and normal endoscopy
Measured: 12 months
Identify predictors of response to empiric dilation in patients with dysphagia and normal endoscopy
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Sep 2011 (estimated)
- Study startSep 2011
- Primary completion24 Oct 2013
- Study completion24 Oct 2013
Why it stopped: poor recruitment
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Dysphagia With Normal EndoscopyStudies of the same condition, open and under way.
- More trials run by Washington University School of MedicineThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 30 participants (actual)
Sponsor and investigators
- Lead sponsor
- Washington University School of Medicine
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01444066
- Sponsor's protocol ID
- 201106053
- Status last verified
- Jun 2020
- First submitted
- 28 Sep 2011
- Last updated
- 18 Jun 2020
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 18 Jun 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Role Of Empiric Dilation In Patients With Dysphagia With Normal Endoscopy
- ClinicalTrials.gov ID
- NCT01444066
- Acronym / sponsor ID
- 201106053
- Conditions
- Dysphagia With Normal Endoscopy
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: poor recruitment
- Enrolment
- 30 participants (actual)
- Lead sponsor
- Washington University School of MedicineUniversity, hospital or other
- Study start
- Sep 2011
- Primary completion
- 24 Oct 2013 (actual)
- Study completion
- 24 Oct 2013 (actual)
- First posted
- 30 Sep 2011 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of our study is to determine if stretching the esophagus with a rubber dilator helps patients with swallowing difficulties who have a normal appearing esophagus on upper endoscopy. In order to do this we will perform a randomized controlled study, where patients will undergo esophageal dilation (stretching) with different diameter dilators. We will measure change in symptom severity between baseline (prior to dilation) and 1, 3, 6 and 12 months after the procedure
Detailed description
Dysphagia typically refers to the sensation of food being stuck in the throat or chest( esophageal dysphagia) as well as difficulty with the initiation of swallowing (oropharyngeal dysphagia). It is typically classified into oropharyngeal and esophageal dysphagia. Oropharyngeal dysphagia is typically the result of neuromuscular disease as well as head and neck malignancy and can be diagnosed on the basis of history and physical examination in most cases. Patients with esophageal dysphagia can further be sub-classified into two groups; those with obvious abnormality in the esophageal mucosa or motility on endoscopy and those with normal findings on endoscopic examination.
The diagnosis and treatment of patients with dysphagia and abnormal findings on endoscopy has been extensively studied and there are well-define practice guidelines availed on the subject. In contrast to this the management strategy for the group of patients with esophageal type dysphagia and a normal appearing esophagus on upper endoscopy (DNE) has been a topic of controversy for over a decade. Those patients with DNE are thought to fall into several categories, those with very subtle strictures and rings in the esophagus that are not seen during endoscopy, as well as patients with non-erosive reflux disease, eosinophilic esophagitis, primary motility disorders of the esophagus, and finally those with "functional" dysphagia (in whom no cause can be identified). Several approaches have been advocated for the evaluation and treatment of patients with DNE, including a trial of proton pump inhibitor therapy, obtaining random biopsies to exclude eosinophilic esophagitis and non-erosive reflux disease, referral for manometry and esophageal pH monitoring, as well as empiric esophageal dilation with a large caliber bougie. Of these options empiric esophageal dilation with a large diameter bougie has been the initial management approach recommended by the most recent AGA guidelines as well as many experts in the field of esophagology, for the treatment of DNE.
The initial evidence for empiric esophageal dilation in patients with DNE came from a retrospective study by Marshal et al, who found that 50% of patients experienced a sustained improvement in symptoms following dilation with a large diameter bougie. This was followed by a randomized controlled trial by Colon and coworkers, who again found a significant benefit to empiric esophageal bougie dilation. However, two randomized trials in the mid-2000's did not find any benefit to empiric esophageal dilation; although the dilation methods used in these studies differed from that used by Marshal and Colon et al. Despite these conflicting results empiric dilation continues to be popular by community gastroenterologists, and is perceived to be safe effective intervention for treating patients with DEN. A recent study by Olson et al found that empiric dilation for DNE was performed more commonly then dilation for dilation for esophageal strictures in the United States and is associated with a 0.65% complication rate. Additionally, in the current era of financial pressure on the medical community empiric dilation for DNE at the time of the first diagnostic upper endoscopy could lead to a significant savings if it is effective in relieving symptoms; by obviating the need for further diagnostic testing, medications and repeat endoscopy.
With this in mind, our goal is to conduct a randomized controlled trial evaluating the role of empiric dilation in patients with DNE, to help fill existing gaps in the medical literature. Specifically, prior studies are lacking with regard to three important points. First, esophageal manometry and pH monitoring were not uniformly performed on patients; this testing is crucial to excluding esophageal motility disorders and non-erosive reflux disease, which are thought to be causes of DNE. Second, esophageal biopsies were not performed in any of the studies; this has become a standard part of the evaluation of all patients with DNE over the past 5 years, as eosinophilic esophagitis and non-erosive reflux disease can lead to dysphagia and may be missed without microscopic examination of the esophageal mucosa. Finally, none of the studies used a standardized and validated dysphagia questionnaire, such as the Mayo Dysphagia Questionnaire (MDQ) to evaluate symptoms.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| dilation to 27 French | Placebo comparator | Procedure: Dilation of the esophagus |
| Dilation of the esophagus to 54 French | Experimental | Procedure: Dilation of the esophagusEsophagus will be dilated with a Savory dilator |
Who may qualify
- Ages
- 18 to 99 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Patients age: > 18 years.
- Outpatients undergoing EGD for dysphagia.
- Ability to provide written informed consent.
Key exclusion criteria (8 listed)
- Abnormal endoscopy (stricture, abnormal motility or mucosa observed)
- Oropharyngeal dysphagia suspected based on history and physical examination
- History of CVA or other neurologic disorder
- Known connective tissue disease (SLE, scleroderma, CREST, RA)
- Known histopathology based esophageal motor disorder, e.g. achalasia
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Dilation of the esophagusEsophagus will be dilated with a Savory dilator. | Procedure or surgery | Dilation of the esophagus to 54 French, dilation to 27 French |
Primary outcome
Improvement in dysphagia, quantified using 10 cm VAS scale
Time frame: 12 months
3 secondary outcomes
Evaluate the yield of esophageal biopsy in patients with dysphagia with normal endoscopy
Time frame: 12 months
Evaluate the yield of HRM and pH monitoring in patients with dysphagia and normal endoscopy
Time frame: 12 months
Identify predictors of response to empiric dilation in patients with dysphagia and normal endoscopy
Time frame: 12 months
Results and safety
The study was stopped early (reason given: poor recruitment). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Jun 2020.
Related trials for Dysphagia With Normal Endoscopy
Active, not recruitingObservational study
Biological Sample Repository for Gastrointestinal Disorders
Obesity, Obesity, Morbid
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Dilation of the esophagus in people with Dysphagia With Normal Endoscopy, run by Washington University School of Medicine at 2 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 18 Jun 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early (reason given: poor recruitment). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Improvement in dysphagia, quantified using 10 cm VAS scale (time frame: 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Jun 2020.